Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

AIMS: Neuromyelitis optica spectrum disorders (NMOSD) is an autoantibody‐mediated, B cell‐driven disease. Inebilizumab is a humanized, affinity‐optimized, afucosylated IgG1 κ monoclonal antibody that binds to the B‐cell specific surface antigen CD19, resulting in rapid, profound and sustained deplet...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Li, Wang, Bing, She, Dewei, Mitchell, Ben, Criste, Ryan, Cimbora, Daniel, Katz, Eliezer, Rees, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545531/
https://www.ncbi.nlm.nih.gov/pubmed/35332558
http://dx.doi.org/10.1111/bcp.15332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545531/
https://www.ncbi.nlm.nih.gov/pubmed/35332558
http://dx.doi.org/10.1111/bcp.15332

Ejemplares similares